Anzeige
Mehr »
Login
Sonntag, 16.02.2025 Börsentäglich über 12.000 News von 686 internationalen Medien
1,5 Mio. Unzen indiziert, 5,2 Mio. Unzen geschätzt - und es wächst weiter: Die Goldaktie mit neuem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A400E3 | ISIN: FR001400N2P2 | Ticker-Symbol: 37S
Stuttgart
14.02.25
14:44 Uhr
0,119 Euro
+0,002
+1,72 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SPINEWAY Chart 1 Jahr
5-Tage-Chart
SPINEWAY 5-Tage-Chart
RealtimeGeldBriefZeit
0,1100,13517:09
GlobeNewswire (Europe)
535 Leser
Artikel bewerten:
(2)

Spineway: 2024 revenue of €12 million - 14% growth compared with 2023

Finanznachrichten News

Press release

Ecully, January 22, 2025 - 6.30 p.m.

SPINEWAY

2024 revenue of €12 million
14% growth compared with 2023

In thousands of euros20242023Change

as a %
H1 revenue6,5355,431+20%
H2 revenue5,4155,088+6%
Full-year revenue11,95010,519+14%

Unaudited consolidated data

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is reporting annual revenue of €11.9 million in FY 2024, representing organic growth of 14% (excluding changes in the scope of consolidation) compared with FY 2023. This acceleration benefited from the successful integration of the Distimp and Spine Innovations acquisitions, which have strengthened the Group's premium ranges and boosted sales in this segment.

Latin America and Asia were the drivers of overall annual growth, thanks to the introduction of these premium and innovative products to the Group's long-standing distributors. Continued sales growth in these regions in the fourth quarter enabled the Group to achieve annual revenue of €3.1 million in Latin America (+35% compared with 2023) and €1.9 million in Asia (+12%). In Europe, after a fourth quarter affected by the delayed launch of new ranges, full-year revenue was up 2.5% year on year at €5.3 million. This growth demonstrates the good positioning of Spineway's products in this demanding and mature market, despite competition exacerbated by stagnant economies and restrictive fiscal policies.

Revenue growth combined with the full impact of cost-cutting measures should help improve the Group's operating performance1 in fiscal 2024.Based on the positive trend in its business, Spineway confirms its aim of becoming a major player in less invasive spine treatments.

Next event:
March 24, 2025 - Annual results for 2024

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.
ISIN: FR001400BVK2 - ALSPW

Contacts:


SPINEWAY

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

AELIUM

Investor relations

Solène Kennis

spineway@aelium.fr

1 In terms of EBITDA and operating income


© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.